Skip to main content

Table 2 Correlations between baseline parameters and the reduction of body weight or HbA1c at 1 year

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Baseline parameters

Reduction of body weight

Reduction of HbA1c

 

Univariate

Multivariate p value

Univariate

Multivariate p value

 

r

p value

 

r

p value

 

Age

0.006

0.955

 

−0.119

0.274

 

Male

−0.129

0.236

 

−0.137

0.209

 

BMI

0.355

0.001

0.007

0.082

0.456

 

WC

0.210

0.114

 

−0.078

0.563

 

Duration of DM

0.087

0.447

 

−0.072

0.533

 

SBP

−0.158

0.146

 

0.002

0.986

 

DBP

−0.050

0.649

 

0.135

0.216

 

FPG

−0.066

0.549

 

−0.113

0.302

 

HbA1c

−0.114

0.295

 

0.564

<0.001

<0.001

LDL-C

0.014

0.897

 

0.203

0.066

0.693

TG

−0.146

0.187

 

0.210

0.056

0.564

HDL-C

−0.014

0.902

 

−0.087

0.432

 

AST

0.224

0.049

 

−0.128

0.265

 

ALT

0.230

0.035

0.091

0.111

0.313

 

sCPR

0.010

0.934

 

0.054

0.662

 

Insulin dose

0.266

0.016

0.461

−0.057

0.611

 

Insulin dose U/kg

0.213

0.055

 

−0.061

0.583

 

Eating behavior

0.247

0.256

 

0.066

0.765

 

Previous treatment

Insulin

0.246

0.022

0.027

−0.225

0.037

0.374

BG

−0.063

0.562

 

0.050

0.645

 

SU

−0.114

0.294

 

−0.046

0.284

 

αGI

−0.046

0.672

 

0.117

0.284

 

TZD

−0.072

0.503

 

0.054

0.622

 

DPP4i

0.060

0.579

 

0.043

0.697

 

Glinide

−0.032

0.770

 

0.046

0.676

 
  1. Reduction of body weight or HbA1c from baseline to 1 year was analyzed with baseline clinical parameters.
  2. BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose, HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase, ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us